Abstract: A mouse model for vein graft stenosis useful for identifying compounds which reduce or prevent such stenosis, consisting of a mouse engrafted with an autogenous vein which exhibits detectable stenosis within 30 days of transplantation. Also disclosed are therapeutic methods for inhibiting the development of vein graft stenosis.

Abstract: h-TREK1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing h-TREK1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: The invention provides histidine kinase polypeptides and polynucleotides encoding histidine kinase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing histidine kinase polypeptides to screen for antibacterial compounds.

Abstract: This invention relates to an intraluminal stent having a lumen-wall contacting surface and a lumen-exposed surface wherein the stent comprises a first polymer composition comprising fibrin and wherein the stent is suitable to deliver virus to the wall of a lumen of the body. The invention also relates to methods for making the stent and to methods for delivering nucleic acid to cells accessible from a wall of a body lumen.

Abstract: This invention is a vaccine prepared from antigen-antibody-recombinant plasmid DNA complex. This invention is a complex vaccine composed of at least one microbial source antigen and its (their) specific antibody or specific immunoglobulin complexed with one or more recombinant DNA(s) from the gene or genes of microbes. Immunization with this complex vaccine induces enhanced specific humoral and cellular immune responses in infected individuals with immune tolerance or immune defects against specific microbial infections. The advantages of this complex vaccine are: antigen presentation via various modes; more rapid induction of immune responses; less amount of components required to induce immune responses; increased stability of the vaccine; and can be applied by injection, intranasal or other routes of topical immunization.

Abstract: A method for inducing and enhancing mammalian mucosal immunity includes the steps of first administering to a mammal via a non-mucosal route a suitable amount of a priming vaccine composition which comprises a DNA sequence encoding an antigen of a pathogen under the control of regulatory sequences directing expression thereof in a mammalian cell, and subsequently, administering intranasally a boosting vaccine composition which comprises the same antigen in protein form or a DNA sequence encoding the same antigen.

Abstract: The present invention relates to transgenic mice which express CREB. These transgenic mice provide a genetic model of dilated cardiomyopathy.

Abstract: Substantially purified stable human hypoxia-inducible factor-1.alpha. (sHIF-1.alpha.) mutein is provided. Polynucleotides encoding stable human hypoxia-inducible factor-1.alpha. mutein are also provided. A method is provided for treating a hypoxia-related tissue damage in a subject by administering to the subject a therapeutically effective amount of a sHIF-1.alpha. mutein or a nucleotide sequence including an expression control sequence operatively linked to a polynucleotide encoding a stable hypoxia-inducible factor-1.alpha. mutein. Formulations are provided for the administration of stable human hypoxia inducible factor-1.alpha. (HIF-1.alpha.) polypeptide or a polynucleotide encoding stable human hypoxia inducible factor-1.alpha. (HIF-1.alpha.) to a patient having hypoxia-related tissue damage.

Abstract: Transgenic mice which constitutively express an antibody-type molecule encoded by the transgene and which has an IgE heavy chain constant region and is specific for a pre-defined antigen, provide an allergic reaction to that antigen without prior sensitization and are useful as allergy models.

Abstract: Transgenic animals expressing Fc receptors and uses for the animals in testing the efficacy of human antibodies and in generating novel antibodies are described.